These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35192389)

  • 21. [Economic effects of "molecular" medicine].
    Riemann JF
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1740. PubMed ID: 17713881
    [No Abstract]   [Full Text] [Related]  

  • 22. Statistical versus quantitative significance in the socioeconomic evaluation of medicines.
    O'Brien BJ; Drummond MF
    Pharmacoeconomics; 1994 May; 5(5):389-98. PubMed ID: 10147230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Concept of Economic Evaluation and Its Application in Thyroid Cancer Research.
    Kim K; Kim M; Lim W; Kim BH; Park SK
    Endocrinol Metab (Seoul); 2021 Aug; 36(4):725-736. PubMed ID: 34474512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-utility analysis of methadone maintenance treatment in Lithuania.
    Vanagas G; Padaiga Z; Bagdonas E
    Medicina (Kaunas); 2010; 46(4):286-92. PubMed ID: 20571298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of childhood anxiety disorder in the context of maternal anxiety disorder: a randomised controlled trial and economic analysis.
    Creswell C; Cruddace S; Gerry S; Gitau R; McIntosh E; Mollison J; Murray L; Shafran R; Stein A; Violato M; Voysey M; Willetts L; Williams N; Yu LM; Cooper PJ
    Health Technol Assess; 2015 May; 19(38):1-184, vii-viii. PubMed ID: 26004142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human erythropoietin: factors to consider in cost-benefit analysis.
    Sheingold SH; Churchill DN; Muirhead N; Laupacis A
    Am J Kidney Dis; 1991 Jan; 17(1):86-92. PubMed ID: 1898836
    [No Abstract]   [Full Text] [Related]  

  • 27. [Economic evaluation of targeted cancer therapy].
    Ikeda S
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):967-70. PubMed ID: 23986036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoglobulin Replacement Therapy is critical and cost-effective in increasing life expectancy and quality of life in patients suffering from Common Variable Immunodeficiency Disorders (CVID): A health-economic assessment.
    van Wilder P; Odnoletkova I; Mouline M; de Vries E
    PLoS One; 2021; 16(3):e0247941. PubMed ID: 33661975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial.
    Weintraub WS; Culler SD; Kosinski A; Becker ER; Mahoney E; Burnette J; Spertus JA; Feeny D; Cohen DJ; Krumholz H; Ellis SG; Demopoulos L; Robertson D; Boccuzzi SJ; Barr E; Cannon CP
    Am J Cardiol; 1999 Feb; 83(3):317-22. PubMed ID: 10072215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Economic aspects. Cost-effectiveness, cost-benefit analysis].
    Durieux P
    Rev Mal Respir; 1998 Sep; 15 Suppl 2():S37-41. PubMed ID: 9809342
    [No Abstract]   [Full Text] [Related]  

  • 31. Economic aspects of haemophilia care.
    Aldedort LM; Miners A; Bohn R; Borrero P; Goudemand J; Hoots K; Kavakli K; Lee C; Roberts J; Schramm W; Szucs T; Wasserman J
    Haemophilia; 1999 May; 5(3):216-9. PubMed ID: 10484669
    [No Abstract]   [Full Text] [Related]  

  • 32. Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT.
    Clarkson JE; Pitts NB; Goulao B; Boyers D; Ramsay CR; Floate R; Braid HJ; Fee PA; Ord FS; Worthington HV; van der Pol M; Young L; Freeman R; Gouick J; Humphris GM; Mitchell FE; McDonald AM; Norrie JD; Sim K; Douglas G; Ricketts D
    Health Technol Assess; 2020 Nov; 24(60):1-138. PubMed ID: 33215986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health-related quality of life in adolescents and young adults with cancer - Including a focus on economic evaluation.
    Barr RD; Feeny DA
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27808. PubMed ID: 31081602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Quality of life of patients treated for terminal chronic renal failure].
    Patte D
    Presse Med; 1998 Oct; 27(29):1499-505. PubMed ID: 9798471
    [No Abstract]   [Full Text] [Related]  

  • 35. Socio-economic aspects of neuroimmunological diseases.
    Rieckmann P
    J Neurol; 2006 Sep; 253 Suppl 5():V87-90. PubMed ID: 16998761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treating osteoporosis: economic aspects of bisphosphonate therapy.
    Kennedy CC; Papaioannou A; Adachi JD
    Expert Opin Pharmacother; 2006 Aug; 7(11):1457-67. PubMed ID: 16859429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Approach to economic analysis in critical care.
    Kyeremanteng K; Wan C; D'Egidio G; Neilipovitz D
    J Crit Care; 2016 Dec; 36():92-96. PubMed ID: 27546754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Study on medical economic evaluation methods for metastatic brain tumors therapy].
    Takura T; Hayashi M; Muragaki Y; Iseki H; Uetsuka Y
    No Shinkei Geka; 2010 Jul; 38(7):629-37. PubMed ID: 20628189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of economic evaluation on quality management in spine surgery.
    Boos N
    Eur Spine J; 2009 Aug; 18 Suppl 3(Suppl 3):338-47. PubMed ID: 19337760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life as an outcome measure for epilepsy clinical trials.
    Cramer JA
    Pharm World Sci; 1997 Oct; 19(5):227-30. PubMed ID: 9368923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.